There has been no shortage of discussion about accelerating clinical development. Over the past decade, life sciences organizations have invested heavily in advanced analytics, cloud computing, automation and, more recently, AI.
These technologies are changing how clinical teams work, helping them analyze information more quickly, automate processes and make decisions with greater confidence.
The potential is significant. If we can reduce the time it takes to design studies, understand emerging results and make decisions, we can ultimately shorten the journey from discovery to patient impact.
But there is a part of that journey that receives considerably less attention.
The time it takes to get the data ready.
This may not sound like the most exciting part of clinical development, but it is becoming increasingly important. Before teams can analyze data, share it with decision-makers or use it to support AI-enabled workflows, they need to bring it together, standardize it and understand it. Teams need to understand its provenance, trust its quality and trace the transformations it has undergone.
That has always been true. What has changed is the scale and complexity of the problem.
A modern clinical study can draw information from electronic data capture systems, laboratories, imaging platforms, wearables, external data providers and real-world data sources. Each brings potentially valuable information, but each can also introduce different structures, standards and requirements.
Bringing those sources together is not simply a matter of moving data from one system to another. It involves understanding what the data means, applying appropriate standards, maintaining its lineage and ensuring teams can ultimately use it with confidence.
And as the volume and variety of clinical data increase, so does the effort required to prepare it.
The AI conversation brings the issue into sharper focus
The growing interest in AI has made this challenge harder to ignore.
Organizations are understandably exploring how generative AI and other forms of AI can help improve productivity, automate repetitive activities, surface insights and support decision-making across the clinical development life cycle. Some of these applications could profoundly change how teams conduct clinical research.
But AI does not remove the fundamental need for good data. In many respects, it makes that need more visible.
AI can process and interpret information at a scale that would be difficult for people alone. But its usefulness still depends on the information people give it and the context surrounding that information. In clinical development, inconsistently defined, poorly structured or difficult-to-trace data can limit how confidently teams can use those capabilities.
That is why organizations increasingly need to consider AI readiness alongside data readiness.
The issue isn’t simply whether an organization has access to AI technology. It is whether the organization sufficiently trusts, standardizes and governs the data underneath the technology to support the decisions that people will ask AI to help them make.
This is an important shift in perspective. Organizations have traditionally viewed data preparation as an operational activity that happens before the more interesting work of analysis begins. But as clinical development becomes more data-intensive and more AI-enabled, that foundation increasingly determines how quickly everything built on top of it can move.
A process designed for a different era
The traditional approach to clinical data transformation has served the industry well. Teams collect, standardize, transform and review data before eventually preparing it for analysis or submission. Given the regulatory environment in which clinical research operates, there are good reasons for the discipline and control that the process requires.
The problem is that the environment around it has changed.
Clinical teams are working with more data sources, more complex studies and a wider range of analytical requirements. Teams may now need data they once prepared for a particular downstream purpose to support multiple analyses, different teams and new forms of automation. Organizations increasingly want to reuse data rather than repeatedly prepare it for individual projects.
That creates an interesting question.
Instead of continually asking how to prepare a particular data set for the next stage of a study, what if we asked how to build a clinical data foundation ready to support whatever comes next?
That is a subtle difference, but an important one.
It moves data transformation away from occurring at specific points in a process and toward becoming a capability that continuously supports the process.
From data preparation to data readiness
There are practical benefits to making that shift.
When teams consistently standardize and govern clinical data, they can spend less time resolving inconsistencies and preparing information for individual activities. Analysts can begin their work sooner. Teams can reuse data more easily. Traceability becomes part of the process rather than **something teams have to reconstruct later.
It can also make collaboration easier.
Clinical, statistical, data management and other teams often need to work with the same underlying information, but may approach it from different perspectives. A trusted and consistently governed data foundation provides a common point of reference.
The value, therefore, extends beyond efficiency. It is about creating greater confidence in the information teams use throughout the development life cycle.
That becomes particularly important as organizations introduce more AI and automation into clinical workflows. The more technology participates in interpreting information and supporting decisions, the more important it becomes to understand and trust the data underneath it.
In that sense, data transformation isn’t just preparation for analysis anymore. It is preparation for a much broader clinical development ecosystem.
Rethinking where clinical acceleration begins
Much of the conversation around clinical acceleration has focused on what happens once teams have prepared the data.
How quickly can we analyze it? How quickly can we generate insights? How quickly can we make decisions?
Those questions remain important. But there is another opportunity that sits earlier in the process.
How quickly can we turn the data generated by a study into information we can trust, reuse and apply to support those activities?
If the answer to that question remains measured in weeks or months of manual preparation and repeated transformation, then accelerating everything downstream will only take us so far.
Therefore, clinical acceleration needs to start earlier. Organizations need to connect data transformation, standardization and governance more closely to the subsequent analysis and regulatory activities. Instead of repeatedly preparing data for each downstream use, teams can work from a common, trusted foundation that supports the clinical development process more broadly.
This approach to clinical data transformation shifts the focus from repeatedly preparing data for individual tasks toward keeping data ready for reuse across clinical workflows.
That shift becomes increasingly important as clinical development moves toward more connected and AI-enabled workflows.
The foundation may determine how far we can go
There is every reason to be excited about what AI, automation and advanced analytics could bring to clinical research. They have the potential to change not only how quickly organizations work, but how they work.
But technology alone will not determine who benefits most from those advances.
Organizations also need to consider the less visible infrastructure underneath them: the standards, governance, lineage and processes that make clinical data trustworthy and reusable.
The industry has spent years finding ways to speed up analytics. The next opportunity is to look further upstream and reduce the time and effort required to prepare clinical data so teams can actually use those capabilities.
Because ultimately, the speed of the analysis is only part of the equation.
If we want to accelerate clinical development, we also need to accelerate the journey to trusted, reusable data.
